Natural killer (NK) cells are emerging as an increasingly important cell type for therapeutic development for multiple diseases. Using induced pluripotent stem cell (iPSC)-derived cell therapies has multiple advantages for developing sophisticated, armored CAR-NK cell therapies.
Edited iPSC-derived CAR-NK cell therapies are a compelling platform for cell therapy development
iPSCs are amenable to higher numbers of genome-editing events than most primary cells, allowing for sophisticated armoring
We have developed robust differentiation and expansion protocols to derive NKs from iPSCs
Using induced pluripotent stem cells (iPSCs), we are able to generate and armor genome-edited CAR-NK cells to address the challenges of treating multiple diseases by armoring cells for targeting, trafficking, proliferation, and overcoming the immunosuppressive tumor microenvironment.
